CNX-1351 is a potent and isoform-selective targeted covalent PI3Kα inhibitor with IC 50 of 6.8 nM. In Vitro CNX-1351 is able to potently (EC 50 In Vivo CNX-1351 inhibits p-Akt Ser473 in mouse spleens and bonds to PI3Kα in vivo. CNX-1351 is delivered into the intraperitoneal cavity of nude mice at 100 mg/kg once a day for 5 consecutive days (n=3 mice per group). Spleens are harvested from the mice at the indicated times after the last dose (1-24 h) and interrogated by immunoblot for P-Akt Ser473 or for PI3Kα occupancy. Inhibition of PI3K signaling is detected as a decrease in P-Akt Ser473 at 1 and 4 h after last dose . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Form:Solid IC50& Target:PI3Kα 6.8 nM (IC 50 ) PI3Kβ 166 nM (IC 50 ) PI3Kδ 240.3 nM (IC 50 ) PI3Kγ 3020 nM (IC 50 )
All
Chemical Reagents
Biomedicine
Organic raw materials
Inorganic chemical industry
intermediate
Agricultural chemicals
Auxiliaries and catalysts
Fragrances and Flavors
Dyes and Pigments
Daily chemical industry
CNX-1351
CAS number：1276105-89-5 molecular formula：C30H35N7O3S
overview
compound introduction
Specs
| Chinese alias | - | ||
| English alias | - | ||
| CAS number | 1276105-89-5 | molecular formula | C30H35N7O3S |
| molecular weight | 573.71 g/mol | Exact mass | ≥99% |
| PSA | 136.000 Ų | logp | 2.900 |
numbering system
No numbering system information yet
physicochemical properties
No physical and chemical property information yet
Safety information
No safety information yet
Production methods and uses
No production method and use information yet
Related
upstream information
No upstream information yet
downstream information
No downstream information yet
MSDS
Found 0 shareMSDS
